Replay announces partnership between product company Syena and JURA Bio to advance T cell ...
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Stay updated with breaking news from David Hafler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
In a first-of-its-kind breakthrough, a study involving over 22,000 multiple sclerosis patients, has identified a genetic variant that speeds up the progression of the disease. A study of more than 22,000 people with multiple sclerosis (MS) has for the first time identified a genetic variant assoc
A new study involving over 22,000 people with Multiple Sclerosis (MS) has identified a genetic variant associated with the disease's faster progression.
A study of more than 22,000 people with multiple sclerosis (MS) has for the first time identified a genetic variant associated with faster progression of the disease, an accumulation of disability that can rob patients of their mobility and independence over time.
A study of more than 22,000 people with MS has for the first time identified a genetic variant associated with faster progression of the disease.